Cetuximab (Erbitux) is a chimeric (mouse/human) monoclonal antibody that is approved by the U.S. Food and Drug Administration for the trea™ent of patients with metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab, as an epidermal growth factor receptor (EGFR) inhibitor, binds to EGFR.